IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
6
Bullish
4
Bearish
19
Neutral
6
Bullish
21
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q4 FY25
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
482.90 | 2,133 Cr | 85.58 | 10.37 | 0.00 | 5.03 | 4.64 | 1.89 | ||
2419.55 | 2,058 Cr | 14.37 | 5.71 | 0.45 | 15.45 | 14.34 | 20.20 | ||
1840.70 | 2,047 Cr | 38.38 | 4.68 | 0.00 | 11.86 | 16.78 | 8.13 | ||
214.50 | 1,980 Cr | 62.31 | 1.94 | 0.09 | -7.71 | 1.93 | 1.22 | ||
20.87 | 1,962 Cr | 22.94 | 4.73 | 0.48 | 18.42 | 24.46 | 16.02 | ||
1454.15 | 1,944 Cr | 15.97 | 2.76 | 0.69 | 17.27 | 22.14 | 14.50 | ||
923.35 | 1,905 Cr | 28.67 | 3.28 | 0.68 | 11.44 | 14.90 | 7.32 | ||
| Median: 7 Co. | — | 923.35 | 1,980 Cr | 28.67 | 4.68 | 0.45 | 11.86 | 14.90 | 8.13 |
Upcoming Result Date: Nov 12, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Syncom Formulations (India) Ltd (SYNCOMF) is currently trading at 20.22 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Syncom Formulations (India) Limited is an established pharmaceutical manufacturer and marketer producing over 200 formulation products across tablets, capsules, liquids, injectables and other dosage forms, operating WHO-GMP and ISO 9001:2015 certified facilities at Pithampur and Palghar, and holding three wholly-owned subsidiaries focused on pharma manufacturing and biotech. The company reported Q1 FY2026-27 standalone revenue from operations of INR 124.66 crore and consolidated revenue of INR 125.53 crore, delivering standalone profit before tax of INR 31.91 crore and standalone PAT of INR 24.59 crore, reflecting roughly 7% year-on-year revenue growth and healthy PBT and PAT margins for the quarter. Pharmaceutical drugs and formulations dominate the revenue mix, contributing the vast majority of quarterly sales while trading and property rental remain immaterial; segment disclosures show large pharma assets and liabilities concentrated in Pithampur operations, indicating product-centric operational leverage and revenue visibility tied to formulations and injectables. The company reported an EPS restatement to align with Ind AS 33 and showed retained reserves and consolidated net assets exceeding INR 527 crore, reflecting a moderate-sized asset base and accumulated reserves that support continued manufacturing investments and provide balance sheet flexibility for Syncom Formulations (India) Limited. Board-approved quarterly results were subject to limited review with unqualified reports, and management emphasised compliance and correction of EPS methodology, signalling governance attention to accounting accuracy and regulatory requirements while maintaining operational focus on capacity and quality certifications.
Over the past 52 weeks, Syncom Formulations (India) Ltd has traded between a low of ₹10.21 and a high of ₹27.53. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Syncom Formulations (India) Ltd has a market capitalization of approximately 1,961.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Syncom Formulations (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.94 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,961.78 Cr, Syncom Formulations (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Syncom Formulations (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Syncom Formulations (India) Ltd is 22.94. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board meeting is scheduled for Tuesday, August 11, 2026 at 4:00 PM IST at the company’s corporate office in Indore.
His resignation as Whole-Time Director and Director is effective August 11, 2026, and the cessation is stated to be from the close of business hours that day.
The 'Biopharma Shakti' initiative, a ₹10,000 crore program to make India a global biopharma manufacturing hub, is the most significant announcement for the pharmaceutical sector, including companies like Syncom.
Syncom Formulations (India) Limited is an established pharmaceutical manufacturer and marketer producing over 200 formulation products across tablets, capsules, liquids, injectables and other dosage forms, operating WHO-GMP and ISO 9001:2015 certified facilities at Pithampur and Palghar, and holding three wholly-owned subsidiaries focused on pharma manufacturing and biotech.
The company reported Q1 FY2026-27 standalone revenue from operations of INR 124.66 crore and consolidated revenue of INR 125.53 crore, delivering standalone profit before tax of INR 31.91 crore and standalone PAT of INR 24.59 crore, reflecting roughly 7% year-on-year revenue growth and healthy PBT and PAT margins for the quarter.
Pharmaceutical drugs and formulations dominate the revenue mix, contributing the vast majority of quarterly sales while trading and property rental remain immaterial; segment disclosures show large pharma assets and liabilities concentrated in Pithampur operations, indicating product-centric operational leverage and revenue visibility tied to formulations and injectables.
The company reported an EPS restatement to align with Ind AS 33 and showed retained reserves and consolidated net assets exceeding INR 527 crore, reflecting a moderate-sized asset base and accumulated reserves that support continued manufacturing investments and provide balance sheet flexibility for Syncom Formulations (India) Limited.
Board-approved quarterly results were subject to limited review with unqualified reports, and management emphasised compliance and correction of EPS methodology, signalling governance attention to accounting accuracy and regulatory requirements while maintaining operational focus on capacity and quality certifications.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,962 Cr
Moderate Risk
22.9
37.9
0.4
4.7
27.53
10.21
Sales CAGR
Profit CAGR
ROE
ROCE
